{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:54:53Z","timestamp":1791176093589,"version":"4.1.0"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,11,1]]},"abstract":"\n Objective.<\/jats:title>\n Revaccination policies adopted in many countries to control measles have raised various safety issues including those concerning the second vaccine dose. We performed a prospective, double-blind, crossover trial among twins receiving a measles-mumps-rubella (MMR) vaccine.<\/jats:p>\n <\/jats:sec>\n \n Study Design.<\/jats:title>\n The study comprised 1162 monozygous and heterozygous twins, each of whom randomly received placebo and then vaccine, or vice versa, 3 weeks apart, at 14 to 83 months of age. Most of the oldest children had previously been vaccinated against measles, and one half of the remainder of children had had the disease. Symptoms and signs were recorded daily on structured forms. Statistical methods included a complex analysis of the vaccine attributability of the symptoms and conditional logistic regression.<\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n Vaccination-attributable events occurred in 6% overall. At 14 to 18 months of age, reactions developed between days 6 and 14, peaking at day 10. The clearest vaccine-attributable effect was fever exceeding 101.3 \u00b0F (38.5\u00b0C; odds ratio: 3.28; 95% confidence interval: 2.23\u20134.82; P &lt; .001), but the same trend was found for rash, arthralgia, conjunctivitis, staying in bed, drowsiness, and irritability. At 6 years of age, systemic reactions occurred 5 to 15 times less frequently, only arthralgia being associated with vaccination. Zygocity, gender, history of allergy, or infections did not modify reactions. Instead, respiratory symptoms developed within days postinjection to a level of 15% to 20% without subsequent decline and with no difference between vaccinees and placebo recipients.<\/jats:p>\n <\/jats:sec>\n \n Conclusion.<\/jats:title>\n Vaccination was avoided during infections, but many small children became mildly ill within a week or so with no relation to vaccination (the healthy vaccinee effect). MMR vaccine was virtually nonreactogenic when given at 6 years of age. vaccine, measles, mumps, rubella, reactogenicity, adverse events, zygocity, healthy vaccinee effect.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.106.5.e62","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:50:41Z","timestamp":1092441041000},"page":"e62-e62","source":"Crossref","is-referenced-by-count":87,"title":["Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination"],"prefix":"10.1542","volume":"106","author":[{"given":"Martti","family":"Virtanen","sequence":"first","affiliation":[{"name":"From the National Research and Development Center for Welfare and Health;"},{"name":"National Public Health Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Peltola","sequence":"additional","affiliation":[{"name":"National Public Health Institute;"},{"name":"Helsinki University Central Hospital, Hospital for Children and Adolescents; and the"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Paunio","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli P.","family":"Heinonen","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2000,11,1]]},"reference":[{"key":"2021121003281231000_B1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM196007282630401","article-title":"Studies on an attenuated measles-virus vaccine: development and preparation of the vaccine: technics for assay of effects of vaccination.","volume":"263","author":"Enders","year":"1960","journal-title":"N Engl J Med"},{"key":"2021121003281231000_B2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF01253813","article-title":"Immunization with live attenuated measles virus vaccines: five years' experience.","volume":"16","author":"Katz","year":"1965","journal-title":"Arch Virusforsch"},{"key":"2021121003281231000_B3","first-page":"175","article-title":"Attenuation and characterization of Edmonston-Zagreb measles vaccine.","volume":"16","author":"Ikic","year":"1972","journal-title":"Ann Immunol Hung"},{"key":"2021121003281231000_B4"},{"key":"2021121003281231000_B5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.1983.03340110023025","article-title":"Antibody response following measles- mumps-rubella vaccine under conditions of customary use.","volume":"250","author":"Brunell","year":"1983","journal-title":"JAMA"},{"key":"2021121003281231000_B6","first-page":"1081","article-title":"Serologic response to revaccination with two rubella vaccines.","volume":"130","author":"Brandling-Bennett","year":"1976","journal-title":"Am J Dis Child"},{"key":"2021121003281231000_B7","first-page":"1978","article-title":"Rubella viraemia and antibody responses after rubella vaccination and reimmunisation.","volume":"1","author":"Balfour","year":"1981","journal-title":"Lancet"},{"key":"2021121003281231000_B8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM196802012780501","article-title":"Live, attenuated mump-virus vaccine.","volume":"278","author":"Hilleman","year":"1968","journal-title":"N Engl J Med"},{"key":"2021121003281231000_B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1542\/peds.68.1.18","article-title":"Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77: DE-5 and RA 27\/3) virus vaccines, singly and in combination.","volume":"68","author":"Lerman","year":"1981","journal-title":"Pediatrics"},{"key":"2021121003281231000_B10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies on combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus.","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"2021121003281231000_B11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/bmj.287.6389.389","article-title":"Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.","volume":"287","author":"Christenson","year":"1983","journal-title":"Br Med J"},{"key":"2021121003281231000_B12","first-page":"843","article-title":"Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.","volume":"138","author":"Vesikari","year":"1984","journal-title":"Am J Dis Child"},{"key":"2021121003281231000_B13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.100.5.767","article-title":"MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink Project.","volume":"100","author":"Davis","year":"1997","journal-title":"Pediatrics"},{"key":"2021121003281231000_B14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(86)91044-5","article-title":"Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind, placebo-controlled trial in twins.","volume":"1","author":"Peltola","year":"1986","journal-title":"Lancet"},{"key":"2021121003281231000_B15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(86)92270-1","article-title":"Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.","volume":"1","author":"Peltola","year":"1986","journal-title":"Lancet"},{"key":"2021121003281231000_B16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/oxfordjournals.aje.a115827","article-title":"Increase of vaccination coverage by mass media and individual approach: Intensified measles, mumps, and rubella prevention program in Finland.","volume":"133","author":"Paunio","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2021121003281231000_B17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","article-title":"The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.","volume":"331","author":"Peltola","year":"1994","journal-title":"N Engl J Med"},{"key":"2021121003281231000_B18"},{"key":"2021121003281231000_B19"},{"key":"2021121003281231000_B20"},{"key":"2021121003281231000_B21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/oxfordjournals.aje.a116479","article-title":"Confounding in studies of adverse reactions to vaccines.","volume":"136","author":"Fine","year":"1992","journal-title":"Am J Epidemiol"},{"key":"2021121003281231000_B22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(05)78423-3","article-title":"Vaccine adverse events: causal or coincidental?","volume":"351","author":"Chen","year":"1998","journal-title":"Lancet"},{"key":"2021121003281231000_B23","first-page":"1","article-title":"Recommendation of the Immunization Practices Advisory Committee (ACIP): measles prevention.","volume":"38","author":"Centers for Disease Control","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121003281231000_B24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/bmj.287.6389.389","article-title":"Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.","volume":"287","author":"Christenson","year":"1983","journal-title":"Br Med J"},{"key":"2021121003281231000_B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/oxfordjournals.aje.a115106","article-title":"An explosive point-source measles outbreak in a highly vaccinated population.","volume":"129","author":"Chen","year":"1989","journal-title":"Am J Epidemiol"},{"key":"2021121003281231000_B26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2307\/30147165","article-title":"Secondary measles vaccine failure in healthcare workers exposed to infected patients.","volume":"14","author":"Ammari","year":"1993","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021121003281231000_B27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00006454-199601000-00014","article-title":"Secondary failure rates of measles vaccines: a metaanalysis of published studies.","volume":"15","author":"Anders","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"2021121003281231000_B28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/00006454-199612000-00005","article-title":"Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus.","volume":"15","author":"Gu\u0308ris","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"2021121003281231000_B29","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0140-6736(05)65134-3","article-title":"No measles in Finland.","volume":"350","author":"Peltola","year":"1997","journal-title":"Lancet"},{"key":"2021121003281231000_B30"},{"key":"2021121003281231000_B31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/jech.53.3.173","article-title":"Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.","volume":"53","author":"Paunio","year":"1999","journal-title":"J Epidemiol Community Health"},{"key":"2021121003281231000_B32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/oxfordjournals.aje.a009588","article-title":"Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees","volume":"148","author":"Paunio","year":"1998","journal-title":". Am J Epidemol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/5\/e62\/841171\/e62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/5\/e62\/841171\/e62.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:12:06Z","timestamp":1639131126000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/106\/5\/e62\/63128\/Day-to-Day-Reactogenicity-and-the-Healthy-Vaccinee"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11,1]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2000,11,1]]},"published-print":{"date-parts":[[2000,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.106.5.e62","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11,1]]}}}